An official website of the United States government
The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before
sharing sensitive information, make sure you’re on a federal
government site.
The site is secure.
The https:// ensures that you are connecting to the
official website and that any information you provide is encrypted
and transmitted securely.
Mitochondrial disorders are a group of genetic diseases affecting the energy-converting process of oxidative phosphorylation. The extreme variability of symptoms, organ involvement, and clinical course represent a challenge to the development of effective therapeutic interventions. However, new possibilities have recently been emerging from studies in model organisms and awaiting verification in humans. I will discuss here the most promising experimental approaches and the challenges we face to translate them into the clinics. The current clinical trials will also be briefly reviewed.
Wallace D.C. (2005) A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine. Annu. Rev. Genet. 39, 359–407 doi:10.1146/annurev.genet.39.110304.095751
-
DOI
-
PMC
-
PubMed
Walker J.E. (2013) The ATP synthase: the understood, the uncertain and the unknown. Biochem. Soc. Trans. 41, 1–16 doi:10.1042/BST20110773
-
DOI
-
PubMed
Zeviani M. and Di Donato S. (2004) Mitochondrial disorders. Brain 127, 2153–2172 doi:10.1093/brain/awh259
-
DOI
-
PubMed
Chinnery P.F. (2015) Mitochondrial disease in adults: what's old and what's new? EMBO Mol. Med. 7, 1503–1512 doi:10.15252/emmm.201505079
-
DOI
-
PMC
-
PubMed
Koopman W.J.H., Willems P.H.G.M. and Smeitink J.A.M. (2012) Monogenic mitochondrial disorders. N. Engl. J. Med. 366, 1132–1141 doi:10.1056/NEJMra1012478
-
DOI
-
PubMed